Yes and it should be complete today. Also insiders bought some nice shares on the offering. They now have around 90 million in cash. Hell Bivigam when it was selling was doing about 50 million a year in sales. I think their revenue will start to really take off.
When Biotest owned Bivigam it was doing about 50 million a year but it was far short due to the manufacturing facility they had and the production problems they ran into. The facility had major problems and that was why the FDA shut them down. With ADMA's new facility I think they can for sure do a lot better then 50 million. Not to mention ADMA has way better commercial connections. I am very strong on this one.
Also to add to this. The other drug that was approved RI-002 has very nice margins. If RI-002 captures just a 5% share of the U.S. IVIG marketplace, it translates into a $200 million annual opportunity, at a 70% gross margin
I think the most important thing to remember is ADMA now controls all their own manufacturing operations. That alone saves a company a ton of money. They have a ton of leverage this way with their drugs.
News 
Market Data 
Discover 
